MA29976B1 - Utilisation d'inhibiteurs de la voie du complement pour traiter des maladies oculaires. - Google Patents
Utilisation d'inhibiteurs de la voie du complement pour traiter des maladies oculaires.Info
- Publication number
- MA29976B1 MA29976B1 MA30972A MA30972A MA29976B1 MA 29976 B1 MA29976 B1 MA 29976B1 MA 30972 A MA30972 A MA 30972A MA 30972 A MA30972 A MA 30972A MA 29976 B1 MA29976 B1 MA 29976B1
- Authority
- MA
- Morocco
- Prior art keywords
- factor
- ocular diseases
- inhibitors
- antibody
- treating ocular
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Mycology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Plant Pathology (AREA)
- Marine Sciences & Fisheries (AREA)
- Ophthalmology & Optometry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Transplantation (AREA)
Abstract
LA PRÉSENTE INVENTION CONCERNE LE TRAITEMENT DE MALADIES ET AFFECTIONS OCULAIRES EN ADMINISTRANT UN INHIBITEUR DE LA VOIE DU COMPLÉMENT, EN PARTICULIER UN INHIBITEUR DE LA VOIE ALTERNE. LES MALADIES OCULAIRES COMPRENNENT LA DÉGÉNÉRESCENCE MACULAIRE LIÉE À L'ÂGE, LA RÉTINOPATHIE DIABÉTIQUE ET L'ANGIOGENÈSE OCULAIRE. UN MODE DE RÉALISATION COMPREND L'ADMINISTRATION D'UN ANTICORPS ANTI-FACTEUR D SOUS LA FORME D'UN ANTICORPS ENTIER, D'UN FRAGMENT FAB OU D'UN ANTICORPS À UN SEUL DOMAINE. D'AUTRES INHIBITEURS DU COMPOSANT COMPLÉMENT QUI PEUVENT ÊTRE UTILES DANS LE PRÉSENT PROCÉDÉ COMPRENNENT LE FACTEUR H OU DES INHIBITEURS QUI BLOQUENT L'ACTION DE LA PROPERDINE, DU FACTEUR B, DU FACTEUR BA, DU FACTEUR BB, DU C2, DU C2A, DU C3A, DU C5, DU C5A, DU C5B, DU C6, DU C7, DU C8, DU C9 OU DU C5B-9.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US73376305P | 2005-11-04 | 2005-11-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA29976B1 true MA29976B1 (fr) | 2008-11-03 |
Family
ID=38023865
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA30972A MA29976B1 (fr) | 2005-11-04 | 2008-05-30 | Utilisation d'inhibiteurs de la voie du complement pour traiter des maladies oculaires. |
Country Status (29)
Country | Link |
---|---|
US (3) | US8753625B2 (fr) |
EP (4) | EP3299027A1 (fr) |
JP (7) | JP2009514888A (fr) |
KR (6) | KR20180002911A (fr) |
CN (2) | CN101355956A (fr) |
AU (1) | AU2006311803C1 (fr) |
BR (1) | BRPI0619657A2 (fr) |
CA (2) | CA2624393C (fr) |
CR (1) | CR10041A (fr) |
DK (1) | DK2500030T4 (fr) |
EC (1) | ECSP088500A (fr) |
ES (1) | ES2551202T5 (fr) |
HK (2) | HK1175718A1 (fr) |
HU (1) | HUE026423T2 (fr) |
IL (3) | IL190547A (fr) |
MA (1) | MA29976B1 (fr) |
MX (3) | MX337061B (fr) |
MY (1) | MY151064A (fr) |
NO (1) | NO20082483L (fr) |
NZ (2) | NZ567483A (fr) |
PH (1) | PH12013501270B1 (fr) |
PL (1) | PL2500030T5 (fr) |
PT (1) | PT2500030E (fr) |
RU (2) | RU2417099C2 (fr) |
SG (1) | SG10201804008UA (fr) |
SI (1) | SI2500030T2 (fr) |
UA (1) | UA99591C2 (fr) |
WO (1) | WO2007056227A2 (fr) |
ZA (2) | ZA200803659B (fr) |
Families Citing this family (107)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT1713503E (pt) | 2004-02-10 | 2013-11-14 | Nat Jewish Health | Inibição do factor b, a via alternativa do complemento e métodos relacionados |
WO2006096561A2 (fr) | 2005-03-04 | 2006-09-14 | Duke University | Variants genetiques augmentant le risque de la degenerescence maculaire liee a l'age |
ES2548700T3 (es) | 2005-05-26 | 2015-10-20 | The Regents Of The University Of Colorado, A Body Corporate | Inhibición de la vía alternativa del complemento para el tratamiento de lesión cerebral traumática, lesión de médula espinal y afecciones relacionadas |
US8168584B2 (en) | 2005-10-08 | 2012-05-01 | Potentia Pharmaceuticals, Inc. | Methods of treating age-related macular degeneration by compstatin and analogs thereof |
WO2007056227A2 (fr) | 2005-11-04 | 2007-05-18 | Genentech, Inc. | Utilisation d'inhibiteurs de la voie du complément pour traiter des maladies oculaires |
CN101563363B (zh) | 2006-06-21 | 2013-01-02 | 南卡罗来纳医疗大学研究发展基金会 | 用于治疗疾病的靶向补体因子h |
PL3028716T3 (pl) | 2006-10-10 | 2021-03-08 | Regenesance B.V. | Hamowanie układu dopełniacza służące do lepszej regeneracji nerwów |
EP2097455B1 (fr) | 2006-11-02 | 2014-10-22 | Genentech, Inc. | Anticorps anti facteur-d humanisés et leurs utilisations |
EP2236518B1 (fr) | 2007-03-14 | 2014-08-06 | Alexion Cambridge Corporation | Anticorps humanisé contre le facteur B |
EP2129681A2 (fr) * | 2007-03-22 | 2009-12-09 | Novartis Ag | Antigènes c5 et leurs utilisations |
WO2009029669A1 (fr) * | 2007-08-27 | 2009-03-05 | Novelmed Therapeutics, Inc. | Procédé d'inhibition d'activation de complément avec des anticorps spécifique de facteur bb |
AR066660A1 (es) | 2007-05-23 | 2009-09-02 | Genentech Inc | Prevencion y tratamiento de condiciones del ojo asociadas con su complemento |
US10131706B2 (en) | 2007-08-27 | 2018-11-20 | Novelmed Therapeutics, Inc. | Anti-factor Bb antibodies |
GB0718737D0 (en) * | 2007-09-25 | 2007-11-07 | Glaxo Group Ltd | Antibodies |
CA2704973A1 (fr) * | 2007-11-08 | 2009-05-14 | Genentech, Inc. | Anticorps anti-facteur b et leurs utilisations |
WO2009111701A2 (fr) * | 2008-03-06 | 2009-09-11 | Case Western Reserve University | Méthode de traitement de troubles médiés par des lymphocytes t |
CR20170001A (es) * | 2008-04-28 | 2017-08-10 | Genentech Inc | Anticuerpos anti factor d humanizados |
AU2013200637B2 (en) * | 2008-04-28 | 2015-07-16 | Genentech, Inc. | Humanized anti-Factor D antibodies and uses thereof |
CA2730203C (fr) * | 2008-07-10 | 2016-12-13 | Academisch Ziekenhuis Bij De Universiteit Van Amsterdam | Antagonistes du complement et leurs utilisations |
WO2010015608A1 (fr) | 2008-08-05 | 2010-02-11 | Novartis Ag | Compositions et procédés pour des anticorps ciblant une protéine du complément c5 |
US8092013B2 (en) * | 2008-10-28 | 2012-01-10 | Johnson & Johnson Vision Care, Inc. | Apparatus and method for activation of components of an energized ophthalmic lens |
US8623395B2 (en) | 2010-01-29 | 2014-01-07 | Forsight Vision4, Inc. | Implantable therapeutic device |
PL2391419T3 (pl) | 2009-01-29 | 2019-12-31 | Forsight Vision4, Inc. | Dostarczanie leku do tylnego odcinka |
RS20120461A1 (en) | 2009-07-02 | 2013-06-28 | Musc Foundation For Research Development | METHODS FOR STIMULATION OF LIVER REGENERATION |
AU2010314931A1 (en) | 2009-11-05 | 2012-06-21 | Taligen Therapeutics, Inc. | Treatment of paroxysmal nocturnal hemoglobinuria, hemolytic anemias and disease states involving intravascular and extravascular hemolysis |
US10166142B2 (en) | 2010-01-29 | 2019-01-01 | Forsight Vision4, Inc. | Small molecule delivery with implantable therapeutic device |
WO2011113641A1 (fr) | 2010-02-12 | 2011-09-22 | Cemm Forschungszentrum Für Molekulare Medizin Gmbh | Facteur h du complément pour états pathologiques de stress oxydatif |
US20130058931A1 (en) | 2010-03-11 | 2013-03-07 | University Of Louisville Research Foundation, Inc. | Methods of predicting and decreasing the risk of pregnancy loss |
AU2011245117B2 (en) | 2010-04-30 | 2015-03-12 | Alexion Pharmaceuticals, Inc. | Anti-C5a antibodies and methods for using the antibodies |
JP5986990B2 (ja) | 2010-05-14 | 2016-09-06 | ザ リージェンツ オブ ザ ユニヴァーシティ オブ コロラド,ア ボディ コーポレート | 改善された補体レセプター2(cr2)ターゲティング基 |
WO2011163412A1 (fr) | 2010-06-22 | 2011-12-29 | The Regents Of The University Of Colorado, A Body Corporate | Anticorps contre le fragment c3d du composant 3 du complément |
US9421240B2 (en) | 2010-06-22 | 2016-08-23 | Apellis Pharmaceuticals, Inc. | Compstatin analogs for treatment of neuropathic pain |
SI2600812T1 (sl) * | 2010-08-05 | 2021-12-31 | ForSight Vision4, Inc., | Naprava za zdravljenje očesa |
US8915877B2 (en) | 2010-10-12 | 2014-12-23 | Emmett T. Cunningham, JR. | Glaucoma drainage device and uses thereof |
US9370444B2 (en) | 2010-10-12 | 2016-06-21 | Emmett T. Cunningham, JR. | Subconjunctival conformer device and uses thereof |
EP2635704B1 (fr) * | 2010-11-01 | 2017-04-19 | F. Hoffmann-La Roche AG | Prédiction de progression vers une dégénérescence maculaire liée à l'âge de stade avancé à l'aide de score polygénique |
US20140031769A1 (en) | 2010-11-19 | 2014-01-30 | Forsight Vision4, Inc. | Therapeutic agent formulations for implanted devices |
EP2646821A4 (fr) | 2010-11-29 | 2015-09-23 | Novelmed Therapeutics Inc | Néoanticorps pour le diagnostic d'une lésion tissulaire |
RU2639521C2 (ru) * | 2011-05-05 | 2017-12-21 | ВЕЛЛСТАТ ИММЬЮНОТЕРАПЬЮТИКС, ЭлЭлСи | Аналоги фактора комплемента в и их применения |
EP4105224A1 (fr) * | 2011-05-11 | 2022-12-21 | Apellis Pharmaceuticals, Inc. | Analogues de la compstatine à longue durée d'action et leurs utilisations |
US10588879B2 (en) * | 2011-08-01 | 2020-03-17 | Aurin Biotech Inc. | Treatment of age-related macular degeneration |
EP3330288A1 (fr) | 2011-12-21 | 2018-06-06 | Novartis AG | Compositions comprenant des anticorps ciblant le facteur p |
PL2817329T3 (pl) * | 2012-02-20 | 2019-07-31 | Swedish Orphan Biovitrum Ab (Publ) | Polipeptydy wiążące z c5 ludzkiego dopełniacza |
US9540626B2 (en) | 2012-03-19 | 2017-01-10 | The Trustees Of The University Of Pennsylvania | Regulator of complement activation and uses thereof |
FR2988298A1 (fr) * | 2012-03-23 | 2013-09-27 | Lfb Biotechnologies | Facteur h pour son utilisation comme molecule antioxydante |
WO2013152020A1 (fr) | 2012-04-03 | 2013-10-10 | Novelmed Therapeutics, Inc. | Anticorps anti-facteur bb humanisés et chimériques, et leurs utilisations |
US9056874B2 (en) | 2012-05-04 | 2015-06-16 | Novartis Ag | Complement pathway modulators and uses thereof |
EP2855529A4 (fr) | 2012-05-24 | 2015-12-09 | Alexion Pharma Inc | Anticorps anti-facteur b humaneered |
ES2584702T3 (es) * | 2012-06-20 | 2016-09-28 | Novartis Ag | Moduladores de ruta del complemento y usos de los mismos |
KR102073312B1 (ko) | 2012-06-27 | 2020-02-05 | 엘지전자 주식회사 | 당뇨망막병증 진단용 마커 및 이의 용도 |
CN102743371A (zh) * | 2012-07-26 | 2012-10-24 | 山东省眼科研究所 | 一种治疗视网膜新生血管性疾病的药物 |
AU2013302441B2 (en) | 2012-08-17 | 2018-05-10 | The Regents Of The University Of Colorado, A Body Corporate | Compositions and methods for detecting complement activation |
US10413620B2 (en) | 2012-08-17 | 2019-09-17 | The Regents Of The University Of Colorado, A Body Corporate | Light-emitting versions of the monoclonal antibody to C3D (MAB 3D29) for imaging |
CA2887050A1 (fr) | 2012-10-04 | 2014-04-10 | Novelmed Therapeutics, Inc. | Anticorps specifiques de voies alternatives pour traiter les maladies hemolytiques |
EP3660033B9 (fr) | 2012-11-15 | 2022-06-22 | Apellis Pharmaceuticals, Inc. | Analogues de la compstatine à longue durée d'action et compositions et méthodes associées |
BR112015018438A2 (pt) * | 2013-01-31 | 2017-07-18 | Seoul Nat Univ R&Db Foundation | anticorpo contra c5 e método para prevenir e tratar doenças relacionadas a complemento |
EP2970269B1 (fr) | 2013-03-14 | 2017-04-19 | Novartis AG | Dérivés de 2-(1h-indol-4-ylméthyl)-3h-imidazo[4,5-b]pyridine-6-carbonitrile comme inhibiteurs du facteur b du complément utiles pour le traitement de maladies ophtalmiques |
CA2905496A1 (fr) | 2013-03-14 | 2014-09-25 | Forsight Vision4, Inc. | Systemes pour l'administration intra-oculaire entretenue de composes a faible solubilite provenant d'un implant de systeme de pose d'orifice |
US10308687B2 (en) | 2013-03-15 | 2019-06-04 | Apellis Pharmaceuticals, Inc. | Cell-penetrating compstatin analogs and uses thereof |
CN105246438B (zh) | 2013-03-28 | 2018-01-26 | 弗赛特影像4股份有限公司 | 用于输送治疗物质的眼科植入物 |
EP2986599A1 (fr) | 2013-04-17 | 2016-02-24 | Pfizer Inc. | Dérivés de n-pipéridin-3-ylbenzamide dans le traitement des maladies cardiovasculaires |
EP3019243A4 (fr) | 2013-07-12 | 2017-03-15 | Ophthotech Corporation | Procédés pour traiter ou prévenir des états ophtalmologiques |
KR20160042438A (ko) * | 2013-08-12 | 2016-04-19 | 제넨테크, 인크. | 보체-연관 상태의 치료를 위한 조성물 및 방법 |
EP3054965B1 (fr) * | 2013-10-07 | 2021-04-14 | Massachusetts Eye & Ear Infirmary | Anticorps anti-facteur d pour le traitement ou la réduction du décollement de rétine |
JP2016535042A (ja) | 2013-10-30 | 2016-11-10 | ノバルティス アーゲー | 2−ベンジル−ベンゾイミダゾール補体因子b阻害剤およびその使用 |
AU2014370404A1 (en) * | 2013-12-24 | 2016-07-07 | Novelmed Therapeutics, Inc. | Compositions and methods of treating ocular diseases |
EP3110845A1 (fr) | 2014-02-27 | 2017-01-04 | Allergan, Inc. | Anticorps anti-bb du facteur de complement |
US10179821B2 (en) | 2014-05-01 | 2019-01-15 | Genentech, Inc. | Anti-factor D antibodies |
BR122023024819A2 (pt) | 2014-06-12 | 2023-12-26 | Ra Pharmaceuticals, Inc. | Uso de um polipeptídeo para inibir a clivagem de c5 em um sistema celular |
CN107106551A (zh) | 2014-08-08 | 2017-08-29 | 弗赛特影像4股份有限公司 | 受体酪氨酸激酶抑制剂的稳定且可溶的制剂和其制备方法 |
BR112017003200B1 (pt) * | 2014-08-20 | 2023-12-26 | Stichting Sanquin Bloedvoorziening | Anticorpos de potenciamento do fator h e seus usos |
EA201791029A1 (ru) | 2014-11-10 | 2017-12-29 | Дженентек, Инк. | Антитела против интерлейкина-33 и их применение |
US9937222B2 (en) | 2015-01-28 | 2018-04-10 | Ra Pharmaceuticals, Inc. | Modulators of complement activity |
JP7261583B2 (ja) | 2015-09-24 | 2023-04-20 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | 補体媒介性疾患を処置するための組成物及び方法 |
BR112018006810A2 (pt) | 2015-10-07 | 2018-10-23 | Apellis Pharmaceuticals Inc | regimes de dosagem |
CN108513585A (zh) | 2015-10-30 | 2018-09-07 | 豪夫迈·罗氏有限公司 | 测量因子d活性和因子d抑制剂效力的方法 |
WO2017075173A2 (fr) | 2015-10-30 | 2017-05-04 | Genentech, Inc. | Anticorps et conjugués anti-facteur d |
US10654932B2 (en) | 2015-10-30 | 2020-05-19 | Genentech, Inc. | Anti-factor D antibody variant conjugates and uses thereof |
CN108697759B (zh) | 2015-12-16 | 2022-08-02 | Ra制药公司 | 补体活性的调节剂 |
US11072661B2 (en) | 2015-12-23 | 2021-07-27 | Sorbonne Universite | Agents that inhibit the binding of CFH to CD11 b/CD18 and uses thereof |
JP2019506159A (ja) | 2016-01-20 | 2019-03-07 | ヴィトリサ セラピューティクス, インコーポレイテッド | D因子を阻害するための組成物および方法 |
PE20190209A1 (es) | 2016-04-04 | 2019-02-07 | Bioverativ Usa Inc | Anticuerpos anti-factor bb del complemento y uso de estos |
UA124734C2 (uk) | 2016-06-14 | 2021-11-10 | Рідженерон Фармасьютікалз, Інк. | Антитіло проти с5 і його застосування |
EP3551210A1 (fr) | 2016-12-07 | 2019-10-16 | RA Pharmaceuticals, Inc. | Modulateurs de l'activité du complément |
WO2018136827A1 (fr) | 2017-01-20 | 2018-07-26 | Vitrisa Therapeutics, Inc. | Compositions à boucle en épingle à cheveux et procédés pour inhiber le facteur d |
US11198725B2 (en) * | 2017-01-30 | 2021-12-14 | Alexion Pharmaceuticals, Inc. | Monovalent anti-properdin antibodies and antibody fragments |
EA201991876A1 (ru) * | 2017-02-10 | 2020-03-13 | Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания | Антитела против фактора d и их применения |
CN110831544B (zh) | 2017-04-07 | 2022-11-18 | 阿佩利斯制药有限公司 | 长效坎普他汀类似物、其组合物的给药方案及其医药用途 |
WO2018191548A2 (fr) | 2017-04-14 | 2018-10-18 | Kodiak Sciences Inc. | Anticorps antagonistes du facteur d du complément et leurs conjugués |
CN111201246B (zh) | 2017-07-11 | 2023-10-27 | 亚力兄制药公司 | 结合补体成分c5或血清白蛋白的多肽及其融合蛋白 |
WO2019075220A1 (fr) * | 2017-10-11 | 2019-04-18 | Bioverativ Usa Inc. | Procédés permettant d'induire une activité de complément |
BR112020010916A2 (pt) | 2017-12-04 | 2020-11-17 | Ra Pharmaceuticals, Inc | moduladores da atividade do complemento |
EP3724226A1 (fr) | 2017-12-13 | 2020-10-21 | Regeneron Pharmaceuticals, Inc. | Associations d'anticorps anti-c5 et utilisations associées |
GB201800620D0 (en) | 2018-01-15 | 2018-02-28 | Univ Manchester | C3b Binding Polypeptide |
MX2020009152A (es) | 2018-03-02 | 2020-11-09 | Kodiak Sciences Inc | Anticuerpos de il-6 y constructos de fusion y conjugados de los mismos. |
AR117565A1 (es) | 2018-04-03 | 2021-08-18 | Ngm Biopharmaceuticals Inc | Agentes de unión a c3 y método de uso de los mismos |
AU2019266548A1 (en) * | 2018-05-10 | 2021-01-07 | Complement Therapeutics Limited | Methods for assessing macular degeneration |
EP3586865A1 (fr) * | 2018-06-21 | 2020-01-01 | Charité - Universitätsmedizin Berlin | Liants d'anaphylatoxine de complément et leur utilisation dans le traitement d'un sujet présentant une plaie oculaire et/ou une fibrose |
JP2022524078A (ja) | 2019-03-08 | 2022-04-27 | ラ ファーマシューティカルズ インコーポレイテッド | 深部組織浸透性c5阻害剤としてのジルコプラン |
CA3134614A1 (fr) | 2019-03-29 | 2020-10-08 | Ra Pharmaceuticals, Inc. | Modulateurs du complement et procedes associes |
US20220211799A1 (en) | 2019-04-24 | 2022-07-07 | Ra Pharmaceuticals, Inc. | Compositions and methods for modulating complement activity |
AU2020313981A1 (en) | 2019-07-17 | 2022-03-03 | Gemini Therapeutics Sub, Inc. | Factor H potentiating antibodies and uses thereof |
KR102428619B1 (ko) | 2019-09-25 | 2022-08-04 | 대구가톨릭대학교산학협력단 | 망막병증 치료용 약물 방출 콘택트렌즈 및 이의 제조방법 |
IL296256A (en) | 2020-03-13 | 2022-11-01 | Genentech Inc | Antibodies against interleukin-33 and uses thereof |
CA3173325A1 (fr) | 2020-04-20 | 2021-10-28 | Graham Parry | Anticorps humanises anti-facteur bb du complement et leurs utilisations |
CN114686481B (zh) * | 2020-12-31 | 2023-08-15 | 北京键凯科技股份有限公司 | 一种抑制cfd表达的干扰rna及其制备方法和应用 |
TW202415387A (zh) * | 2022-06-30 | 2024-04-16 | 美商伊維希比奥公司 | 用於治療眼科疾患之持續釋放二氧化矽水凝膠複合物及其使用方法 |
Family Cites Families (144)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5022A (en) * | 1847-03-20 | Alfred stillman | ||
US4444887A (en) | 1979-12-10 | 1984-04-24 | Sloan-Kettering Institute | Process for making human antibody producing B-lymphocytes |
US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
US4474893A (en) | 1981-07-01 | 1984-10-02 | The University of Texas System Cancer Center | Recombinant monoclonal antibodies |
US4714681A (en) | 1981-07-01 | 1987-12-22 | The Board Of Reagents, The University Of Texas System Cancer Center | Quadroma cells and trioma cells and methods for the production of same |
US4716111A (en) | 1982-08-11 | 1987-12-29 | Trustees Of Boston University | Process for producing human antibodies |
US4741900A (en) | 1982-11-16 | 1988-05-03 | Cytogen Corporation | Antibody-metal ion complexes |
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
GB2183662B (en) | 1985-04-01 | 1989-01-25 | Celltech Ltd | Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same |
US4980286A (en) | 1985-07-05 | 1990-12-25 | Whitehead Institute For Biomedical Research | In vivo introduction and expression of foreign genetic material in epithelial cells |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
US5618920A (en) | 1985-11-01 | 1997-04-08 | Xoma Corporation | Modular assembly of antibody genes, antibodies prepared thereby and use |
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
US5256642A (en) | 1988-04-01 | 1993-10-26 | The Johns Hopkins University | Compositions of soluble complement receptor 1 (CR1) and a thrombolytic agent, and the methods of use thereof |
WO1989012624A2 (fr) | 1988-06-14 | 1989-12-28 | Cetus Corporation | Agents de couplage et conjugues lies a des disulfures a empechement sterique prepares a partir de tels agents |
US4925648A (en) | 1988-07-29 | 1990-05-15 | Immunomedics, Inc. | Detection and treatment of infectious and inflammatory lesions |
US5601819A (en) | 1988-08-11 | 1997-02-11 | The General Hospital Corporation | Bispecific antibodies for selective immune regulation and for selective immune cell binding |
DE68913658T3 (de) | 1988-11-11 | 2005-07-21 | Stratagene, La Jolla | Klonierung von Immunglobulin Sequenzen aus den variablen Domänen |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
ZA902949B (en) | 1989-05-05 | 1992-02-26 | Res Dev Foundation | A novel antibody delivery system for biological response modifiers |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
DE69029036T2 (de) | 1989-06-29 | 1997-05-22 | Medarex Inc | Bispezifische reagenzien für die aids-therapie |
US5413923A (en) | 1989-07-25 | 1995-05-09 | Cell Genesys, Inc. | Homologous recombination for universal donor cells and chimeric mammalian hosts |
US5436146A (en) | 1989-09-07 | 1995-07-25 | The Trustees Of Princeton University | Helper-free stocks of recombinant adeno-associated virus vectors |
GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
JP3068180B2 (ja) | 1990-01-12 | 2000-07-24 | アブジェニックス インコーポレイテッド | 異種抗体の生成 |
US5314995A (en) | 1990-01-22 | 1994-05-24 | Oncogen | Therapeutic interleukin-2-antibody based fusion proteins |
WO1991014438A1 (fr) | 1990-03-20 | 1991-10-03 | The Trustees Of Columbia University In The City Of New York | Anticorps chimeriques utilisant des ligands de liaison de recepteurs a la place de leur region constante |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
ATE158021T1 (de) | 1990-08-29 | 1997-09-15 | Genpharm Int | Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper |
US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
AU660629B2 (en) | 1990-10-01 | 1995-07-06 | University Of Connecticut, The | Targeting viruses and cells for selective internalization by cells |
AU667460B2 (en) | 1990-10-05 | 1996-03-28 | Medarex, Inc. | Targeted immunostimulation with bispecific reagents |
ATE160379T1 (de) | 1990-10-29 | 1997-12-15 | Chiron Corp | Bispezifische antikörper, verfahren zu ihrer herstellung und deren verwendungen |
EP1149913A1 (fr) | 1990-11-09 | 2001-10-31 | GILLIES, Stephen D. | Immunoconjugués de cytokine |
US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
WO1992019973A1 (fr) | 1991-04-26 | 1992-11-12 | Surface Active Limited | Nouveaux anticorps et procedes d'utilisation de ces anticorps |
DE69231736T2 (de) | 1991-05-14 | 2001-10-25 | The Immune Response Corp., Carlsbad | Gerichtete abgabe von genen, die immunogene proteine kodieren |
DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
CA2103371C (fr) | 1991-06-05 | 2003-09-16 | George Y. Wu | Administration ciblee de genes codant pour des proteines de secretion |
WO1992022653A1 (fr) | 1991-06-14 | 1992-12-23 | Genentech, Inc. | Procede de production d'anticorps humanises |
ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
WO1993008829A1 (fr) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions induisant la destruction de cellules infectees par l'hiv |
EP0617706B1 (fr) | 1991-11-25 | 2001-10-17 | Enzon, Inc. | Proteines multivalentes de fixation aux antigenes |
PT1024191E (pt) | 1991-12-02 | 2008-12-22 | Medical Res Council | Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos |
WO1993014188A1 (fr) | 1992-01-17 | 1993-07-22 | The Regents Of The University Of Michigan | Virus cible |
CA2372813A1 (fr) | 1992-02-06 | 1993-08-19 | L.L. Houston | Proteine fixatrice biosynthetique pour marqueur du cancer |
CA2452130A1 (fr) | 1992-03-05 | 1993-09-16 | Francis J. Burrows | Agents diagnostiques et/ou therapeutiques cibles pour les cellules endotheliales neovasculaires |
EP0633943A4 (fr) | 1992-04-03 | 1997-05-02 | Alexander T Young | Therapie genique utilisant des vecteurs viraux cibles. |
ZA932522B (en) | 1992-04-10 | 1993-12-20 | Res Dev Foundation | Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens |
WO1993025788A1 (fr) | 1992-06-09 | 1993-12-23 | Hoppe Ag | Systeme de loquet et d'ensemble serrure |
US5456909A (en) | 1992-08-07 | 1995-10-10 | T Cell Sciences, Inc. | Glycoform fractions of recombinant soluble complement receptor 1 (sCR1) having extended half-lives in vivo |
WO1994004670A1 (fr) | 1992-08-26 | 1994-03-03 | President And Fellows Of Harvard College | Utilisation de la cytokine ip-10 comme agent antitumeur |
US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
DK0671923T3 (da) | 1992-10-09 | 2001-08-13 | Advanced Tissue Sciences Inc | Leverreserveceller |
WO1994012649A2 (fr) | 1992-12-03 | 1994-06-09 | Genzyme Corporation | Therapie genique de la fibrose kystique |
US5861156A (en) | 1993-01-08 | 1999-01-19 | Creative Biomolecules | Methods of delivering agents to target cells |
DK0698097T3 (da) | 1993-04-29 | 2001-10-08 | Unilever Nv | Produktion af antistoffer eller (funktionaliserede) fragmenter deraf afledt af Camelidae-immunoglobuliner med tung kæde |
US5856300A (en) | 1994-05-12 | 1999-01-05 | T Cell Sciences, Inc. | Compositions comprising complement related proteins and carbohydrates, and methods for producing and using said compositions |
US5679546A (en) | 1993-09-24 | 1997-10-21 | Cytomed, Inc. | Chimeric proteins which block complement activation |
US5627264A (en) | 1994-03-03 | 1997-05-06 | Alexion Pharmaceuticals, Inc. | Chimeric complement inhibitor proteins |
AU2191795A (en) | 1994-03-23 | 1995-10-09 | Alexion Pharmaceuticals, Inc. | Method for reducing immune and hemostatic dysfunctions during extracorporeal circulation |
US5534615A (en) | 1994-04-25 | 1996-07-09 | Genentech, Inc. | Cardiac hypertrophy factor and uses therefor |
US6074642A (en) | 1994-05-02 | 2000-06-13 | Alexion Pharmaceuticals, Inc. | Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis |
WO2000053758A2 (fr) | 1999-03-08 | 2000-09-14 | Genentech, Inc. | Compositions et methodes de traitement des maladies immunitaires |
US5679564A (en) | 1994-10-05 | 1997-10-21 | Antex Biologics, Inc. | Methods for producing enhanced antigenic campylobacter bacteria and vaccines |
DE69637481T2 (de) | 1995-04-27 | 2009-04-09 | Amgen Fremont Inc. | Aus immunisierten Xenomäusen stammende menschliche Antikörper gegen IL-8 |
AU2466895A (en) | 1995-04-28 | 1996-11-18 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
CA2230758A1 (fr) | 1995-09-08 | 1997-03-13 | Genzyme Corporation | Vecteurs aav ameliores pour la therapie genique |
AU5711196A (en) | 1996-03-14 | 1997-10-01 | Human Genome Sciences, Inc. | Apoptosis inducing molecule i |
EP0904278A4 (fr) | 1996-03-22 | 1999-09-15 | Human Genome Sciences Inc | Molecule ii inductrice d'apoptose |
US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
KR20080059467A (ko) | 1996-12-03 | 2008-06-27 | 아브게닉스, 인크. | 복수의 vh 및 vk 부위를 함유하는 사람 면역글로불린유전자좌를 갖는 형질전환된 포유류 및 이로부터 생성된항체 |
US20050197285A1 (en) | 1997-03-07 | 2005-09-08 | Rosen Craig A. | Human secreted proteins |
WO2001036432A2 (fr) | 1999-11-19 | 2001-05-25 | Human Genome Sciences, Inc. | 18 proteines secretees humaines |
US6472520B2 (en) | 1997-03-21 | 2002-10-29 | The Trustees Of Columbia University In The City Of New York | Rat PEG-3 promoter |
WO1998046645A2 (fr) | 1997-04-14 | 1998-10-22 | Micromet Gesellschaft Für Biomedizinische Forschung Mbh | Nouveau procede de production de recepteurs d'anti-antigenes humains et leur utilisation |
US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
US6410708B1 (en) | 1997-11-21 | 2002-06-25 | Genentech, Inc. | Nucleic acids encoding A-33 related antigen polypeptides |
ATE335511T1 (de) | 1997-08-26 | 2006-09-15 | Amgen Fremont Inc | Ein verfahren zur inhibierung der komplementaktivierung über einen alternativen weg |
US6642051B1 (en) | 1997-10-21 | 2003-11-04 | Targeted Genetics Corporation | Amplifiable adeno-associated virus(AAV) packaging cassettes for the production of recombinant AAV vectors |
CN1174993C (zh) | 1997-11-03 | 2004-11-10 | 人体基因组科学有限公司 | Vegi,一种血管发生和肿瘤生长的抑制剂 |
US6595142B2 (en) | 1997-11-13 | 2003-07-22 | M.C.M. Holding A/S | Floor for a transport means and profiles for the construction thereof as well as a vehicle provided with such a floor |
US7282565B2 (en) | 1998-03-20 | 2007-10-16 | Genentech, Inc. | PRO362 polypeptides |
US8007798B2 (en) * | 1997-11-21 | 2011-08-30 | Genentech, Inc. | Treatment of complement-associated disorders |
US8088386B2 (en) * | 1998-03-20 | 2012-01-03 | Genentech, Inc. | Treatment of complement-associated disorders |
US7419663B2 (en) | 1998-03-20 | 2008-09-02 | Genentech, Inc. | Treatment of complement-associated disorders |
EP1481990B1 (fr) | 1997-11-21 | 2007-06-06 | Genentech, Inc. | Antigènes apparentés à A33 et leurs utilisations pharmacologiques |
US7192589B2 (en) | 1998-09-16 | 2007-03-20 | Genentech, Inc. | Treatment of inflammatory disorders with STIgMA immunoadhesins |
CA2320625A1 (fr) | 1998-02-09 | 1999-08-12 | Human Genome Sciences, Inc. | 45 proteines humaines secretees |
US7112327B2 (en) | 1998-02-20 | 2006-09-26 | Tanox, Inc. | Inhibition of complement activation |
CA2321140C (fr) | 1998-02-20 | 2015-04-07 | Tanox, Inc. | Inhibiteurs de l'activation du complement |
US6956107B2 (en) | 1998-02-20 | 2005-10-18 | Tanox, Inc. | Inhibitors of complement activation |
ES2312205T3 (es) | 1998-03-10 | 2009-02-16 | Genentech, Inc. | Nuevo polipeptido y acidos nucleicos que lo codifican. |
JP2002523089A (ja) | 1998-08-27 | 2002-07-30 | インサイト・ファーマスーティカルズ・インコーポレイテッド | タンパク質輸送関連分子 |
EP1141285A2 (fr) | 1998-12-16 | 2001-10-10 | Genentech, Inc. | Polypeptides secretes et transmembranaires et acides nucleiques codant pour ceux-ci |
MXPA01006330A (es) | 1998-12-22 | 2002-07-02 | Genentech Inc | Metodos y composiciones para inhibir el crecimiento de celulas neoplasticas. |
KR20060067983A (ko) | 1999-01-15 | 2006-06-20 | 제넨테크, 인크. | 효과기 기능이 변화된 폴리펩티드 변이체 |
DE60045681D1 (de) | 1999-03-11 | 2011-04-14 | Merck Serono Sa | Vaskuläre adhesionsmoleküle und modulierung ihrer funktion |
US6642353B1 (en) | 1999-03-17 | 2003-11-04 | Chugai Seiyaku Kabushiki Kaisha | Peptide ligands for the erythropoietin receptor |
AU2883900A (en) | 1999-07-07 | 2001-01-30 | Genentech Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
CA2490909A1 (fr) | 1999-12-01 | 2001-06-07 | Genentech, Inc. | Polypeptides secretes et transmembranaires et acides nucleiques codant ces polypeptides |
US6821775B1 (en) * | 2000-02-11 | 2004-11-23 | Genvec, Inc. | Viral vector encoding pigment epithelium-derived factor |
AU2001249410A1 (en) | 2000-03-23 | 2001-10-03 | Tanox, Inc. | Anti-c2/c2a inhibitors of complement activation |
ATE412185T1 (de) * | 2000-04-29 | 2008-11-15 | Univ Iowa Res Found | Diagnostika und therapeutika für makula degeneration erkrankungen |
EP1309620A2 (fr) | 2000-06-23 | 2003-05-14 | Genentech, Inc. | Compositions et procedes de diagnose et traitement de maladies faisant intervenir l'angiogenese |
CA2416538A1 (fr) | 2000-07-20 | 2002-01-31 | Genentech, Inc. | Compositions et methodes diagnostiques et therapeutiques de troubles impliquant l'angiogenese |
EP2113516B1 (fr) | 2000-10-10 | 2014-05-21 | Genentech, Inc. | Anticorps contre C5 inhibant l'activation de type II des cellules endothéliales |
CN1547590A (zh) | 2000-10-13 | 2004-11-17 | ¸ | 人源化抗-LT-β-R抗体 |
US20040077575A1 (en) * | 2002-01-11 | 2004-04-22 | Giordano Giovan Giacomo | Inhibition of pathological angiogenesis in vivo |
US6867189B2 (en) † | 2001-07-26 | 2005-03-15 | Genset S.A. | Use of adipsin/complement factor D in the treatment of metabolic related disorders |
US7432356B2 (en) | 2001-08-17 | 2008-10-07 | Genentech, Inc. | Complement pathway inhibitors binding to C5 and C5a without preventing formation of C5b |
AR040778A1 (es) | 2002-08-06 | 2005-04-20 | Glaxo Group Ltd | Anticuerpos alterados o fragmentos funcionales que se unen a mag (glicoproteina asociada a mielina). |
WO2004022594A2 (fr) | 2002-09-06 | 2004-03-18 | Cytos Biotechnology Ag | Methodes et composes d'immunomodulation |
US7816497B2 (en) * | 2002-10-30 | 2010-10-19 | University Of Kentucky | Compositions and methods for inhibiting drusen complement components C3a and C5a for the treatment of age-related macular degeneration |
US20060140939A1 (en) * | 2003-02-21 | 2006-06-29 | Fung Sek C M | Methods for preventing and treating tissue damage associated with ischemia-reperfusion injury |
RU2232991C1 (ru) | 2003-04-09 | 2004-07-20 | Государственное учреждение "Московский научно-исследовательский институт эпидемиологии и микробиологии им. Г.Н. Габричевского" | Способ определения функциональной активности фактора d комплемента человека |
US7709610B2 (en) | 2003-05-08 | 2010-05-04 | Facet Biotech Corporation | Therapeutic use of anti-CS1 antibodies |
WO2005014849A2 (fr) * | 2003-07-03 | 2005-02-17 | Euro-Celtique, S.A. | Genes associes a des reponses a des douleurs neuropathiques |
WO2005025509A2 (fr) | 2003-09-11 | 2005-03-24 | Board Of Regents, The University Of Texas System | Methodes et matieres de traitement de maladies et de troubles auto-immuns |
JP2007527865A (ja) * | 2003-09-12 | 2007-10-04 | ザ・レジェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア | 種々の配列を有するタンパク質から形成されたアミロイドに共通の高分子量凝集中間体に特異的なモノクローナル抗体 |
US20050169921A1 (en) | 2004-02-03 | 2005-08-04 | Leonard Bell | Method of treating hemolytic disease |
US7794713B2 (en) | 2004-04-07 | 2010-09-14 | Lpath, Inc. | Compositions and methods for the treatment and prevention of hyperproliferative diseases |
AU2005314461B2 (en) | 2004-11-18 | 2012-02-02 | The Rockefeller University | Methods and compositions for treating ocular disorders |
WO2006071856A2 (fr) | 2004-12-23 | 2006-07-06 | Glycofi, Inc. | Immunoglobulines comprenant principalement une glycoforme man5glcnac2 |
WO2006088950A2 (fr) * | 2005-02-14 | 2006-08-24 | University Of Iowa Research Foundation | Procedes et reactifs pour le traitement et le diagnostic de la degenerescence maculaire liee a l'age |
PL1951279T3 (pl) * | 2005-10-08 | 2017-12-29 | Apellis Pharmaceuticals, Inc. | Kompstatyna i jej analogi w zaburzeniach oczu |
WO2007056227A2 (fr) | 2005-11-04 | 2007-05-18 | Genentech, Inc. | Utilisation d'inhibiteurs de la voie du complément pour traiter des maladies oculaires |
US20070190057A1 (en) | 2006-01-23 | 2007-08-16 | Jian Wu | Methods for modulating mannose content of recombinant proteins |
EP2097455B1 (fr) | 2006-11-02 | 2014-10-22 | Genentech, Inc. | Anticorps anti facteur-d humanisés et leurs utilisations |
AR066660A1 (es) | 2007-05-23 | 2009-09-02 | Genentech Inc | Prevencion y tratamiento de condiciones del ojo asociadas con su complemento |
CR20170001A (es) | 2008-04-28 | 2017-08-10 | Genentech Inc | Anticuerpos anti factor d humanizados |
-
2006
- 2006-11-04 WO PCT/US2006/043103 patent/WO2007056227A2/fr active Application Filing
- 2006-11-04 EP EP17186993.6A patent/EP3299027A1/fr not_active Withdrawn
- 2006-11-04 MX MX2011003503A patent/MX337061B/es unknown
- 2006-11-04 MY MYPI20081426 patent/MY151064A/en unknown
- 2006-11-04 KR KR1020177037729A patent/KR20180002911A/ko not_active Application Discontinuation
- 2006-11-04 KR KR1020137030524A patent/KR20130137716A/ko not_active Application Discontinuation
- 2006-11-04 SG SG10201804008UA patent/SG10201804008UA/en unknown
- 2006-11-04 AU AU2006311803A patent/AU2006311803C1/en not_active Ceased
- 2006-11-04 KR KR1020197006092A patent/KR20190026048A/ko not_active Application Discontinuation
- 2006-11-04 PT PT121720015T patent/PT2500030E/pt unknown
- 2006-11-04 CA CA2624393A patent/CA2624393C/fr not_active Expired - Fee Related
- 2006-11-04 KR KR1020167036246A patent/KR20170002684A/ko not_active Application Discontinuation
- 2006-11-04 US US12/092,346 patent/US8753625B2/en not_active Expired - Fee Related
- 2006-11-04 SI SI200631974T patent/SI2500030T2/sl unknown
- 2006-11-04 CN CNA2006800504810A patent/CN101355956A/zh active Pending
- 2006-11-04 EP EP15172358.2A patent/EP2998318A1/fr not_active Withdrawn
- 2006-11-04 NZ NZ567483A patent/NZ567483A/en not_active IP Right Cessation
- 2006-11-04 ZA ZA200803659A patent/ZA200803659B/xx unknown
- 2006-11-04 EP EP06836941A patent/EP1942922A4/fr not_active Withdrawn
- 2006-11-04 ES ES12172001.5T patent/ES2551202T5/es active Active
- 2006-11-04 BR BRPI0619657-8A patent/BRPI0619657A2/pt not_active IP Right Cessation
- 2006-11-04 PL PL12172001T patent/PL2500030T5/pl unknown
- 2006-11-04 HU HUE12172001A patent/HUE026423T2/en unknown
- 2006-11-04 NZ NZ594285A patent/NZ594285A/xx not_active IP Right Cessation
- 2006-11-04 RU RU2008122341/15A patent/RU2417099C2/ru not_active IP Right Cessation
- 2006-11-04 JP JP2008539095A patent/JP2009514888A/ja not_active Withdrawn
- 2006-11-04 KR KR1020087013385A patent/KR101511787B1/ko active IP Right Grant
- 2006-11-04 UA UAA200807619A patent/UA99591C2/ru unknown
- 2006-11-04 KR KR1020157011618A patent/KR20150055628A/ko not_active Application Discontinuation
- 2006-11-04 CN CN201711120837.XA patent/CN107929731A/zh active Pending
- 2006-11-04 MX MX2016001813A patent/MX360959B/es unknown
- 2006-11-04 CA CA2903896A patent/CA2903896A1/fr not_active Abandoned
- 2006-11-04 DK DK12172001.5T patent/DK2500030T4/en active
- 2006-11-04 EP EP12172001.5A patent/EP2500030B2/fr active Active
-
2008
- 2008-04-01 IL IL190547A patent/IL190547A/en not_active IP Right Cessation
- 2008-04-30 MX MX2018014357A patent/MX2018014357A/es unknown
- 2008-05-03 CR CR10041A patent/CR10041A/es unknown
- 2008-05-30 MA MA30972A patent/MA29976B1/fr unknown
- 2008-06-03 NO NO20082483A patent/NO20082483L/no not_active Application Discontinuation
- 2008-06-04 EC EC2008008500A patent/ECSP088500A/es unknown
-
2009
- 2009-09-04 JP JP2009205369A patent/JP2009280626A/ja active Pending
-
2010
- 2010-12-21 RU RU2010152367/15A patent/RU2583927C2/ru not_active IP Right Cessation
-
2012
- 2012-12-10 JP JP2012269482A patent/JP2013049724A/ja not_active Withdrawn
-
2013
- 2013-01-24 ZA ZA2013/00649A patent/ZA201300649B/en unknown
- 2013-03-14 HK HK13103212.1A patent/HK1175718A1/zh not_active IP Right Cessation
- 2013-06-17 PH PH12013501270A patent/PH12013501270B1/en unknown
-
2014
- 2014-05-06 US US14/270,848 patent/US20140335078A1/en not_active Abandoned
-
2015
- 2015-01-29 JP JP2015015014A patent/JP2015083609A/ja not_active Withdrawn
- 2015-06-08 JP JP2015115473A patent/JP2015157862A/ja active Pending
-
2016
- 2016-09-23 HK HK16111213.0A patent/HK1223106A1/zh unknown
-
2017
- 2017-02-20 JP JP2017028964A patent/JP2017095522A/ja not_active Withdrawn
- 2017-02-26 IL IL250772A patent/IL250772A0/en unknown
- 2017-12-15 US US15/844,391 patent/US20180334495A1/en not_active Abandoned
-
2018
- 2018-11-22 IL IL263237A patent/IL263237A/en unknown
- 2018-12-21 JP JP2018238998A patent/JP2019043963A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA29976B1 (fr) | Utilisation d'inhibiteurs de la voie du complement pour traiter des maladies oculaires. | |
MA30462B1 (fr) | Composes de pyridylamide antagonistes des canaux calciques de type t | |
DE602006019948D1 (de) | Koppelten rezeptors zur behandlung von makuladegeneration | |
MA30806B1 (fr) | Phosphoindoles enantiomeriquement purs utilisables en tant qu'inhibiteurs du vih | |
MA30868B1 (fr) | Derives de 2-aminocarbonyl-pyridine | |
TWI372061B (en) | Use of il-23 and il-17 antagonists to treat autoimmune ocular inflammatory disease | |
MA42145B1 (fr) | Triazoles agonistes du récepteur apj | |
MX2022005782A (es) | Anticuerpos monoclonales contra la proteina amiloide beta y usos de los mismos. | |
EP2239328A3 (fr) | Procédés et compositions pour traiter une maladie neurologique | |
MA32804B1 (fr) | Antagonistes d'isonicotinamide des récepteurs de l'orexine | |
KR101155294B1 (ko) | 면역특이적으로 BLyS에 결합하는 항체 | |
WO2008029276A3 (fr) | Compositions et procédés de traitement d'une maladie ophtalmique | |
NO20060328L (no) | Kombinasjon av mGluR2-antagonist og ACHE-inhibitor for behandiing av akutt og/eller kronisk neurologiske forstyrrelser | |
EP2862867A3 (fr) | Procédés et compositions pour le traitement du syndrome de Marfan et troubles associés | |
TW200733976A (en) | Method for the treatment of cognitive dysfunction | |
MA30903B1 (fr) | Derives de 2 - phenyl-6-minocarbonyl-pyrimidine | |
MX2008016525A (es) | Inhibidores heterocíclicos fusionados de d-amino ácido oxidasa. | |
MA31757B1 (fr) | Traitement de symptomes vasomoteurs | |
WO2008057599A3 (fr) | Procédés de traitement de troubles associés à l'abeta et compositions | |
FR3056908B1 (fr) | Sel de metformine et d'elafibranor presentant une activite duale pour le traitement de l'obesite associee a la steato-hepatite non alcoolique (nash) et a l'hypertriglyceridemie | |
MX2007012991A (es) | Formas solidas cristalinas y amorfas de halofenato (-) y metodoss relacionados a las mismas. | |
MA50320A1 (fr) | Formulations orales liquides pour inhibiteurs de pde v | |
MA35580B1 (fr) | Composition pharmaceutique |